Cargando…

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference

Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage. Once daily injection of liraglutide significantly ameliorate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yabe, Daisuke, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411533/ https://www.ncbi.nlm.nih.gov/pubmed/22879794 http://dx.doi.org/10.4137/CMED.S5976

Ejemplares similares

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Retrospective analysis of safety and efficacy of insulin‐to‐liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β‐cell function
por: Usui, Ryota, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
por: Onishi, Yukiko, et al.
Publicado: (2015)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
por: Tonoike, Mie, et al.
Publicado: (2018)

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
por: Usui, Ryota, et al.
Publicado: (2019)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Neumiller, Joshua J, et al.
Publicado: (2010)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β‐cell function and the achievement of the glycated hemoglobin target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2017)

Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2011)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
por: Seino, Yutaka, et al.
Publicado: (2017)

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial
por: Kaneko, Shizuka, et al.
Publicado: (2018)

Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
por: Yamada, Yuichiro, et al.
Publicado: (2021)

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β‐cell function and the achievement of the HbA1c target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2018)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
por: Ito, Daisuke, et al.
Publicado: (2015)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea
por: Jiang, Wenlong, et al.
Publicado: (2022)

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2021)

The Asian Association for the Study of Diabetes: The first 10 years and the next 10 years
por: Seino, Yutaka, et al.
Publicado: (2020)

A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes
por: Kubota, Sodai, et al.
Publicado: (2020)

Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients
por: Zameer, Rafia, et al.
Publicado: (2020)

A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes
por: Liang, Ying, et al.
Publicado: (2021)

Liraglutide in the management of type 2 diabetes
por: Wajcberg, Estela, et al.
Publicado: (2010)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Dietary recommendations for type 2 diabetes patients: Lessons from recent clinical and basic research in Asia
por: Seino, Yusuke, et al.
Publicado: (2019)

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
por: Edavalath, Mahamood, et al.
Publicado: (2010)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Efficacy and safety of liraglutide in Indian adolescents with obesity
por: Kochar, I. S., et al.
Publicado: (2019)

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial
por: Seino, Yutaka, et al.
Publicado: (2016)

Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
por: Wilbrink, Francis J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t6i75ujo899ib4895t6kaska1t